# A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation

> **NCT07625215** · PHASE2 · RECRUITING · sponsor: **Bayer** · enrollment: 360 (estimated)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** BAY 3670549
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07625215
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2030-05-16
- **Final completion:** 2030-05-16
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2026-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07625215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07625215, "A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07625215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*